PubMed COVID-19 Clinical Care
5861 - 5870 of 5967 results found
Covid-19: UK stockpiles two unapproved antiviral drugs for treatment at home
Description
No abstract
Clonal hematopoiesis is associated with risk of severe Covid-19
Description
Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced age, increased risk of cardiovascular and malignant diseases, and decreased overall survival. These adverse sequelae may
Challenges of peer assisted learning in online clinical skills training of ophthalmology module
Description
CONCLUSION: The challenges explored by our study can be used by the medical educators to incorporate online PAL as an effective, efficient, and alternative teaching and learning modality in the curriculum especially in compromised circumstances like
Covid-19 crisis impact on the next generation of physicians: a survey of 800 medical students
Description
CONCLUSION: Medical students of the University of Paris North who made an early and unconditional commitment to help hospital staff handle the pandemic constituted a powerful healthcare reserve force during the crisis. Although the vast majority
COVID-19 in Pediatrics
Description
This article reviews the diagnosis and treatment of infection with severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019, as well as a new inflammatory syndrome after severe acute respiratory syndrome coronavirus 2
Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case-control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC)
Description
CONCLUSIONS: Cardiovascular pathology was diagnosed in 6 symptomatic soldiers (12%) after recovery from SARS-CoV-2, with myocarditis found in 4 (8%). RVEF was reduced in soldier cases compared to controls. CV PASC occurred in over one-third of
COVID-19 Use Causes Tocilizumab Shortage
Description
Based on mounting evidence that tocilizumab improves survival in critically ill patients with COVID-19, the FDA granted it an emergency use authorization for COVID-19 treatment in June. Two months later, the agency added tocilizumab to its list of
